What This Report Will Provide?

This study involved four major activities in estimating the current size of the epigenetics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Expected Revenue Growth:

[230 Pages Report] The global epigenetics market is projected to reach USD 1.60 billion by 2022 from USD 0.85 billion in 2016, at a CAGR of 13.3% from 2017 to 2022.

Major Growth Boosters:

The growth in epigenetics market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the market in the coming years.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896

Selected Market Dynamics of Epigenetics:

Raising Cancer Prevalence:

Globally, there has been a significant increase in the number of people suffering from cancer. According to WHO estimates, the number of people suffering from cancer is expected to increase to 19.3 million by 2025 from 14.1 million in 2012. Cancer is the second leading cause of death in the US and accounts for nearly 1 in every 4 deaths.

Epigenetic changes such as dysregulation of DNA methylation are associated with cancer development and progression. Epigenetics provides new opportunities for deriving therapeutic strategies designed to reverse dysregulation in cancer. Several cancer research studies that utilize epigenetics techniques are currently underway; significant investments are being made to support these researches. The increasing prevalence of cancer will drive epigenetics research focused on this condition.

Major Market Developments:

In July 2017, Agilent launched AriaDx Real-Time PCR System

In June 2017, Illumina launched Extended RAS Panel, a NGS kit

In January 2017, Illumina entered into an agreement with Koninklijke Philips (Netherlands) to integrate Ilumina’s sequencing systems with Philips’ IntelliSpace Genomics clinical informatics platform for oncology

Application of Epigenetics in Oncology:

Oncology is one of those applications where epigenetics technology is extensively used for deriving therapeutic strategies designed to reverse transcriptional abnormalities inherent to the cancer epigenome. The disruption of epigenetic modifications, such as DNA methylation and histone modification, results in altered gene function or expression and cellular transformation leading cancer. Epigenetics assists in the development of inhibitors of DNA methyltransferases and histone deacetylases (HDACs), which have been found to be clinically effective in cancer treatment, attesting to the value of epigenetic therapies in oncology.

Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=896

Key Players:

The global epigenetics market is characterized by a large number of players. The prominent players of this market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), Bio-Rad (US). These companies are pursuing several organic and inorganic growth strategies such as acquisitions, collaboration, partnerships, agreements, expansions, and product launches.